Major Shareholder Announcement

In accordance with section 29 of the Danish Securities Trading Act, Novozymes has been informed that Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Ltd, has decreased its holding of B shares in Novozymes to 7.56%

In accordance with section 29 of the Danish Securities Trading Act, Novozymes hereby announces that it has been informed that Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, has decreased its holding of B shares in Novozymes to 7.56%, previously reported at 7.64% (a decrease of 0.08%).
Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, now holds B shares in Novozymes A/S to a total of 24,556,257 shares of a nominal value of DKK 49,112,514, equivalent to 7.56% of Novozymes A/S’ share capital and 3.04% of the voting rights. The announcement is a result of Baillie Gifford Overseas Limited, a wholly owned subsidiary of Baillie Gifford & Co, increasing its holding of B shares in Novozymes A/S to a total of 16,349,463 B shares of a nominal value of DKK 32,698,926, equivalent to 5.03% of Novozymes share capital.
                                                                                                                                         
 
 
Contact persons:
Press and media:
Investor relations:
René Tronborg (Europe)
Tel. (direct): +45 4446 2274
Tel. (mobile): +45 3077 2274
 
Paige Donnelly (USA)
Tel. (direct): +1 919 494 3209
Tel. (mobile): +1 919 218 4501
Maarit Pokkinen
Tel. (direct): +45 4446 8682
Tel. (mobile): +45 3077 8682
 
Martin Riise
Tel. (direct): +45 4446 0738
Tel. (mobile): +45 3077 0738
 
Thomas Bomhoff (USA)
Tel. (direct): +1 919 494 3483
Tel. (mobile):  +1 919 649 2565